Drugs / ISIS-GCCRRx
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01968265 Comparator | Oct 2013 → Jan 2015 | type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS-GCCRRx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01968265 ↗ |
| Known as | ISIS 426115 | “ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist)” NCT01968265 ↗ |
| Action | Inhibit | “an Antisense Glucocorticoid Receptor Antagonist” NCT01968265 ↗ |
| Modality | Antisense oligonucleotide | “ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist)” NCT01968265 ↗ |
| Route | Subcutaneous | “Administered Subcutaneously” NCT01968265 ↗ |